• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca selects Cambridge, U.K. for R&D center and corporate headquarters

AstraZeneca selects Cambridge, U.K. for R&D center and corporate headquarters

June 20, 2013
CenterWatch Staff

AstraZeneca is building a new $514 million global R&D center and corporate headquarters on the Cambridge Biomedical Campus. By 2016, the new site will house 2,000 employees.

The investment is part of AZ’s move to create strategic global R&D centers in the U.K., U.S. and Sweden to improve pipeline productivity and establish AZ as a global leader in biopharmaceutical innovation.

The site will bring together small molecule and biologics R&D activity, opening up opportunities to small and large molecule combinations. The Cambridge Biomedical Campus will be the new U.K. home for biologics research and protein engineering carried out by MedImmune, AZ’s biologics arm.

The site also will become the company’s largest center for oncology research, as well as cardiovascular and metabolic disease, respiratory, inflammation and autoimmune disease and central nervous system research. The facility also will hold preclinical capabilities including medicinal chemistry and high-throughput screening.

The Cambridge Biomedical Campus is home to research, academic and healthcare organizations including the University of Cambridge school of Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of Metabolic Science and the Cancer Research U.K. Cambridge Institute.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing